AACR 2026: Crown Bioscience Showcases Integrated Platforms Enabling Next-Generation Oncology Modalities, Including ADCs and Radiopharmaceuticals

Contributed by: Business Wire

Tags

Science

Other Science

Radiology

Research

Pharmaceutical

Oncology

Health

Clinical Trials

Crown Bioscience

More Like This

Crown Bioscience Announces New Preclinical and Translational Oncology Data Across Ten Poster Presentations at AACR 2024

Crown Bioscience Expands Singapore Facility with Advanced Oncology Models and Imaging Capabilities

AACR 2025: Crown Bioscience Unveils 3D Bone Marrow Niche In Vitro Models for Oncology Preclinical Screening in Hematological Malignancies

Crown Bioscience and NEXT Oncology Cement Partnership Extension

JSR Life Sciences Enters Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings Limited

Crown Bioscience celebrate the official ribbon-cutting ceremony for the company’s new Kannapolis, North Carolina facility, marking an expansion of US oncology model development and preclinical CRO services.

Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina

Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening

Crown Bioscience's Global Oncology Research Facilities Achieve Prestigious ISO and CAP Accreditations